Changes in the USP heparin monograph and implications for clinicians.
Smythe
Maureen A
MA
Department of Pharmaceutical Services, Beaumont Hospital, Royal Oak, Michigan 48073, USA. msmythe@beaumont.edu
Nutescu
Edith A
EA
Wittkowsky
Ann K
AK
D000925:Anticoagulants / Q000008:administration & dosage / Q000737:chemistry / Q000592:standards* / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D004340:Drug Contamination / Q000517:prevention & control; D016903:Drug Monitoring; D006493:Heparin / Q000008:administration & dosage / Q000737:chemistry / Q000592:standards* / Q000627:therapeutic use*; D006801:Humans; D010602:Pharmacopoeias as Topic; D011516:Prothrombin / Q000037:antagonists & inhibitors; D012015:Reference Standards; D012955:Societies, Medical; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization
D000925:Anticoagulants; D011516:Prothrombin; C025337:Factor IIa; D006493:Heparin